Growth Metrics

Quest Diagnostics (DGX) Net Income towards Common Stockholders (2016 - 2026)

Quest Diagnostics has reported Net Income towards Common Stockholders over the past 18 years, most recently at -$40.0 million for Q1 2026.

  • Quarterly results put Net Income towards Common Stockholders at -$40.0 million for Q1 2026, down 121.74% from a year ago — trailing twelve months through Mar 2026 was $637.0 million (down 18.33% YoY), and the annual figure for FY2025 was $968.0 million, up 11.65%.
  • Net Income towards Common Stockholders reached -$40.0 million in Q1 2026 per DGX's latest filing, down from $213.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $304.0 million in Q1 2022 and bottomed at -$40.0 million in Q1 2026.
  • Median Net Income towards Common Stockholders over the past 5 years was $199.0 million (2024), compared with a mean of $184.3 million.
  • The largest annual shift saw Net Income towards Common Stockholders surged 113.16% in 2023 before it tumbled 121.74% in 2026.
  • Over 5 years, Net Income towards Common Stockholders stood at $76.0 million in 2022, then soared by 113.16% to $162.0 million in 2023, then grew by 20.99% to $196.0 million in 2024, then rose by 8.67% to $213.0 million in 2025, then crashed by 118.78% to -$40.0 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for DGX at -$40.0 million in Q1 2026, $213.0 million in Q4 2025, and $214.0 million in Q3 2025.